Article
Summit Therapeutics is Currently Enrolling in a Phase III Study with Additional Phase III Study Planned for Third Quarter 2023 for Ivonescimab Excerpt from the Press Release: MENLO PARK, Calif.–(BUSINESS WIRE)–Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be…
Read More
The study will build upon previous studies conducted by Ghosh and her collaborators that have explored the ways social inequality contribute to unequal cancer control outcomes Excerpt from the Press Release: n January of this year, Debarchana (Debs) Ghosh, associate professor in the Department of Geography in the College of Liberal Arts and Sciences (CLAS)…
Read More
Phase 1 Findings Demonstrated that Investigational Agent AX-158 Was Well Tolerated at All Doses, with a Profile that Strongly Supports Further Clinical Development Efforts AX-158 is Being Developed for Once Daily Oral Dosing to Address Autoimmune Diseases by Providing Immunomodulation without Immunosuppression Excerpt from the Press Release: CAMBRIDGE, Mass., June 1, 2023 /PRNewswire/ — Artax Biopharma, Inc., a…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Pionyr Immunotherapeutics, Inc., a company developing first-in-class Myeloid Tuning™ antibody therapeutics that enhance the body’s antitumor immunity by altering, or “tuning,” immune cells within the tumor microenvironment, announced today that PY159, a monoclonal antibody targeting TREM1 (triggering receptor expressed on macrophages 1), was well-tolerated with signals…
Read More
Excerpt from the Press Release: eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced positive interim data updates from a Phase 2 expansion cohort evaluating zotatifin combined with fulvestrant and abemaciclib (ZFA triplet) in patients with ER+ metastatic breast cancer (mBC).…
Read More
Excerpt from the Press Release: Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) today announced the data from its Phase 1 dose-escalation clinical trial of BDC-1001 that will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, being held at McCormick Place in Chicago, Illinois and virtually from June 2-6,…
Read More
Excerpt from the Press Release: A paralysed man has regained the ability to walk smoothly using only his thoughts for the first time, researchers said on Wednesday, thanks to two implants that restored communication between brain and spinal cord. The patient Gert-Jan, who did not want to reveal his surname, said the breakthrough had given…
Read More
-FLX475-treated patients exhibited significant changes in immune pathways likely to enhance an antitumor response -FLX475 modifies the tumor microenvironment (TME) to resemble those of responders to anti-PD(L)1 monotherapy Excerpt from the Press Release: RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients…
Read More
New data in ASCO 2023 abstract show continued trend in decreasing Tregs and eosinophils, bolstering novel mechanism of action of AU-007, Aulos’ computationally designed antibody in the IL-2 class Initial anti-tumor activity has been observed since the ASCO data cutoff date, with additional data anticipated by year-end as the Phase 1/2 trial continues to enroll…
Read More
Excerpt from the Press Release: Canada has one of the highest rates of Multiple Sclerosis (MS) in the world — a chronic condition for which there is no cure. But a new research breakthrough at the University of Toronto has the potential to improve the lives of those living with the disease far beyond current…
Read More